ATE486890T1 - Ephb-rezeptorbindende peptide - Google Patents
Ephb-rezeptorbindende peptideInfo
- Publication number
- ATE486890T1 ATE486890T1 AT06733967T AT06733967T ATE486890T1 AT E486890 T1 ATE486890 T1 AT E486890T1 AT 06733967 T AT06733967 T AT 06733967T AT 06733967 T AT06733967 T AT 06733967T AT E486890 T1 ATE486890 T1 AT E486890T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor binding
- binding peptides
- peptides
- ephb receptor
- patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64785205P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002923 WO2006081418A2 (en) | 2005-01-27 | 2006-01-26 | Ephb receptor-binding peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486890T1 true ATE486890T1 (de) | 2010-11-15 |
Family
ID=36606084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06733967T ATE486890T1 (de) | 2005-01-27 | 2006-01-26 | Ephb-rezeptorbindende peptide |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7582438B2 (de) |
| EP (1) | EP1841790B1 (de) |
| JP (1) | JP2008528614A (de) |
| KR (1) | KR20070118230A (de) |
| CN (1) | CN101146822A (de) |
| AT (1) | ATE486890T1 (de) |
| AU (1) | AU2006208068B2 (de) |
| CA (1) | CA2595892A1 (de) |
| DE (1) | DE602006017964D1 (de) |
| WO (1) | WO2006081418A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028551A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| AU2005295158A1 (en) * | 2004-10-18 | 2006-04-27 | Medimmune, Llc | High cell density process for growth of Listeria |
| EP1841790B1 (de) | 2005-01-27 | 2010-11-03 | The Burnham Institute | Ephb-rezeptorbindende peptide |
| US8343461B2 (en) | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| EP2946786A1 (de) | 2006-03-08 | 2015-11-25 | Wake Forest University Health Sciences | Lösliches monomeres Ephrin-A1 |
| JP2009221107A (ja) * | 2006-05-24 | 2009-10-01 | Aqumen Biopharmaceuticals Kk | エフリンｂ２の活性を高めるペプチド，その塩，医薬用組成物，治療用キット |
| EP2061489A4 (de) * | 2006-09-15 | 2009-12-23 | Burnham Inst | Hochaffine ephb-rezeptorbindende verbindungen und anwendungsverfahren dafür |
| US20080112954A1 (en) * | 2006-11-10 | 2008-05-15 | Parker College Of Chiropractic | Method for treating chronic pain |
| CA2680589A1 (en) | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
| US20110009323A1 (en) * | 2007-06-15 | 2011-01-13 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
| US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| US20100240594A1 (en) * | 2009-03-20 | 2010-09-23 | Burnham Institute For Medical Research | Targeted delivery of chemotherapeutic agents |
| US20120207743A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases |
| US20120207734A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases |
| WO2013106824A1 (en) * | 2012-01-13 | 2013-07-18 | Board Of Regents, The University Of Texas System | Epherin receptor targeting agents |
| WO2013108869A1 (ja) * | 2012-01-20 | 2013-07-25 | 国立大学法人岡山大学 | がんの治療又は予防剤 |
| CN105694891B (zh) * | 2015-12-30 | 2018-01-23 | 深圳先进技术研究院 | 一种用于荧光寿命编码的量子点及其荧光寿命编码方法 |
| CN105906691B (zh) * | 2016-07-05 | 2019-09-13 | 珠海诺贝尔国际生物医药研究院有限公司 | 一种Eph激酶多肽抑制剂及其应用 |
| CN106153920B (zh) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| US12448425B2 (en) | 2019-05-08 | 2025-10-21 | Board Of Regents, The University Of Texas System | Therapeutic peptides |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1333777C (en) | 1988-07-01 | 1995-01-03 | Randy M. Berka | Aspartic proteinase deficient filamentous fungi |
| AU685765B2 (en) | 1992-11-13 | 1998-01-29 | Amgen, Inc. | (Eck) receptor ligands |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| PT669929E (pt) | 1992-11-13 | 2007-04-30 | Immunex Corp | Ligando de elk, uma citoquina |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5624899A (en) | 1994-07-20 | 1997-04-29 | Genentech Inc. | Method for using Htk ligand |
| US5795734A (en) | 1994-09-19 | 1998-08-18 | President And Fellows Of Harvard College | EPH receptor ligands, and uses related thereto |
| ATE346498T1 (de) | 1994-10-05 | 2006-12-15 | Immunex Corp | Als lerk6 bezeichnetes cytokin |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US5759775A (en) | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
| WO1996013518A1 (en) | 1994-10-27 | 1996-05-09 | Genentech, Inc. | Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| DK0871702T3 (da) | 1994-12-06 | 2005-09-19 | Immunex Corp | Cytokin betegnet Lerk-7 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| WO1996026958A2 (en) | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | Eph RECEPTOR LIGAND ELF-2 |
| US6001964A (en) | 1995-09-20 | 1999-12-14 | Albert Einstein College Of Medicine Of Yeshiva University | Peptides which bind to anti-double stranded DNA antibody |
| JP2001521368A (ja) | 1996-03-21 | 2001-11-06 | イミュネックス・コーポレーション | Ｌｅｒｋ―８と称すサイトカイン |
| EP0864956A3 (de) * | 1997-03-12 | 1999-03-31 | Texas Instruments Incorporated | Spannungsregler mit niedrigem Spannungsabfall |
| WO1999008696A1 (en) | 1997-08-19 | 1999-02-25 | Vanderbilt University | METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS |
| EP1060249A1 (de) | 1998-03-02 | 2000-12-20 | The Government of the United States represented by the Secretary of the Department of Health and Human Services | Epitope peptiden, die immunogenes gegen streptococcus pneumoniae sind |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| EP1090033B2 (de) | 1998-06-24 | 2007-12-19 | Innogenetics N.V. | Hcv hüllproteine partikel : verwendung für therapeutische impfung |
| ATE293989T1 (de) | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
| AU1764200A (en) | 1998-12-18 | 2000-07-12 | Mount Sinai Hospital Corporation | Three dimensional structure of a sterile alpha motif domain |
| JP4658423B2 (ja) | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
| WO2002026827A1 (en) * | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
| CA2452578A1 (en) | 2001-07-03 | 2003-01-16 | The Hospital For Sick Children | Ephrin and eph receptor mediated immune modulation |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| EP1606305A4 (de) * | 2003-03-12 | 2009-06-24 | Vasgene Therapeutics Inc | Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum |
| WO2004091375A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| EP1841790B1 (de) | 2005-01-27 | 2010-11-03 | The Burnham Institute | Ephb-rezeptorbindende peptide |
| EP2061489A4 (de) | 2006-09-15 | 2009-12-23 | Burnham Inst | Hochaffine ephb-rezeptorbindende verbindungen und anwendungsverfahren dafür |
-
2006
- 2006-01-26 EP EP06733967A patent/EP1841790B1/de not_active Expired - Lifetime
- 2006-01-26 CA CA002595892A patent/CA2595892A1/en not_active Abandoned
- 2006-01-26 KR KR1020077019396A patent/KR20070118230A/ko not_active Ceased
- 2006-01-26 AT AT06733967T patent/ATE486890T1/de not_active IP Right Cessation
- 2006-01-26 WO PCT/US2006/002923 patent/WO2006081418A2/en not_active Ceased
- 2006-01-26 DE DE602006017964T patent/DE602006017964D1/de not_active Expired - Lifetime
- 2006-01-26 JP JP2007553261A patent/JP2008528614A/ja active Pending
- 2006-01-26 AU AU2006208068A patent/AU2006208068B2/en not_active Expired - Fee Related
- 2006-01-26 US US11/342,247 patent/US7582438B2/en not_active Expired - Fee Related
- 2006-01-26 CN CNA200680009759XA patent/CN101146822A/zh active Pending
-
2009
- 2009-08-28 US US12/549,953 patent/US7999069B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1841790A2 (de) | 2007-10-10 |
| KR20070118230A (ko) | 2007-12-14 |
| CN101146822A (zh) | 2008-03-19 |
| US20100183510A1 (en) | 2010-07-22 |
| EP1841790B1 (de) | 2010-11-03 |
| HK1108702A1 (en) | 2008-05-16 |
| US7999069B2 (en) | 2011-08-16 |
| CA2595892A1 (en) | 2006-08-03 |
| AU2006208068A1 (en) | 2006-08-03 |
| US20060177452A1 (en) | 2006-08-10 |
| JP2008528614A (ja) | 2008-07-31 |
| AU2006208068B2 (en) | 2011-08-04 |
| WO2006081418A3 (en) | 2006-12-07 |
| US7582438B2 (en) | 2009-09-01 |
| DE602006017964D1 (de) | 2010-12-16 |
| WO2006081418A2 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006017964D1 (de) | Ephb-rezeptorbindende peptide | |
| CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| ATE502052T1 (de) | Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii) | |
| MY169272A (en) | Her2 antibody composition | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| EA201100923A1 (ru) | Антитела человека против тканевого фактора | |
| NO20076021L (no) | Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme | |
| CY1115935T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| UA107921C2 (en) | Variants of polypeptide of receptor ivr activin and their use | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| CY2017013I1 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
| CL2008002886A1 (es) | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. | |
| UA107490C2 (uk) | TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК | |
| DK1957539T3 (da) | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| EA201071126A1 (ru) | Антагонисты рецепторов глюкагона | |
| BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
| NO20082345L (no) | Selektive VPAC2 reseptorpeptidagonister | |
| ATE404225T1 (de) | Radiofluorierte peptide | |
| ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |